Literature DB >> 12426295

Lung injury linked to etanercept therapy.

Laura Peno-Green1, Geronomo Lluberas, Thomas Kingsley, Steven Brantley.   

Abstract

Etanercept is the first anticytokine drug approved to treat rheumatoid arthritis. Side effects are infrequent, the most common being local skin reactions, headaches, and upper respiratory tract symptoms. We report the first case of lung injury that occurred while receiving this agent. Biopsy specimens of lung and skin lesions demonstrated noncaseating granulomas associated with a microscopic particulate. Withdrawal of etanercept achieved clinical stabilization, and the addition of prednisone resulted in rapid improvement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426295     DOI: 10.1378/chest.122.5.1858

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

Review 1.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

2.  Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab.

Authors:  Andrew J K Ostor; Adrian J Crisp; Margaret F Somerville; David G I Scott
Journal:  BMJ       Date:  2004-11-27

3.  Use of digital x ray radiogrammetry in the assessment of joint damage in rheumatoid arthritis.

Authors:  W B Jawaid; D Crosbie; J Shotton; D M Reid; A Stewart
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

4.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.

Authors:  Peter Korsten; Nadera J Sweiss; Ulf Nagorsnik; Timothy B Niewold; Hermann-Josef Gröne; Oliver Gross; Gerhard A Müller
Journal:  Am J Kidney Dis       Date:  2010-10-25       Impact factor: 8.860

Review 5.  Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature.

Authors:  Theoni Kanellopoulou; Anna Filiotou; Hariklia Kranidioti; Spyridon P Dourakis
Journal:  Clin Rheumatol       Date:  2010-10-23       Impact factor: 2.980

6.  Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association?

Authors:  Muhammad Haroon; John G Ryan; Sinead Harney
Journal:  Clin Rheumatol       Date:  2011-03-08       Impact factor: 2.980

Review 7.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

8.  Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis.

Authors:  S K Metyas; R M Tadros; D G Arkfeld
Journal:  Rheumatol Int       Date:  2008-09-02       Impact factor: 2.631

9.  Development of sarcoidosis following etanercept treatment: a report of three cases.

Authors:  Inger Marie Skoie; Klaus Wildhagen; Roald Omdal
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

10.  Rheumatoid lung disease.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2007-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.